Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | TACR2 | P21452 | 1/20 | 0.35 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.35 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TACR3 | P29371 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12545725 | 0.81 | CHRM4 (0.39) | SLC18A3CHRM4TEAD1TEAD3MAPT | |
| SCHEMBL6399672 | 0.81 | GPR119 (0.45) | — | |
| SCHEMBL27660322 | 0.79 | GAA (0.39) | SLC18A3CHRM4TACR2TEAD1TEAD3 | |
| SCHEMBL25288406 | 0.78 | GPR119 (0.34) | TEAD1TEAD3TACR3L3MBTL1ALDH1A1 | |
| SCHEMBL2126084 | 0.78 | GPR119 (0.34) | TEAD1TEAD3TACR3L3MBTL1ALDH1A1 | |
| SCHEMBL2126089 | 0.78 | GPR119 (0.34) | TEAD1TEAD3TACR3L3MBTL1ALDH1A1 | |
| SCHEMBL14272699 | 0.78 | GNAI3 (0.40) | MAPTTACR3L3MBTL1ALDH1A1 | |
| SCHEMBL4523791 | 0.75 | AKR1C3 (0.46) | TACR3BRD4 | |
| SCHEMBL2337182 | 0.75 | AKR1C3 (0.46) | TACR3BRD4 | |
| SCHEMBL2337183 | 0.75 | AKR1C3 (0.46) | TACR3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504432-B2 | Ester derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20070129397-A1 | Ester derivatives | MSD K.K. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-7192969-B2 | Ester derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20050065211-A1 | Ester derivatives | MSD K.K. (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1302458-A1 | ESTER DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129397-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | SLC18A3 628/4885CHRM4 4/4885TACR2 186/4885 |
| US-20050065211-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | SLC18A3 647/4885CHRM4 4/4885TACR2 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.